DaltonTx, a London, UK-based technology company that provides AI-enabled platforms for drug discovery, has raised £4 million in a seed funding round.
Investors
The round includes redalpine, IQ Capital Partners, and Seedcamp, with additional support from Oxford University Innovation.
DaltonTx Use of Funds
The funding will support the development of DaltonTx’s adaptive AI discovery platform, integration into pharma, biotech, and CRO workflows, and the scaling of its technology.
About DaltonTx
Founded by Dr. Garry Pairaudeau, Adrian Rossall, Dr. Anthony Bradley, and Professor Charlotte Deane, DaltonTx focused on transforming drug discovery with adaptive AI-enabled platforms. Its platform is designed for both small molecules and biologics, facilitating collaboration between human insight and machine learning to optimize R&D outcomes. DaltonTx’s disease- and technology-agnostic platform integrates directly into scientific workflows. The platform supports the full research process, from raw data and model training to molecular design, synthesis, and decision-making.
Funding Details
Company: DaltonTx
Raised: £4.0M
Round: Seed
Funding Date: September 2025
Lead Investors: redalpine, IQ Capital Partners, Seedcamp
Additional Investors: Oxford University Innovation
Company Website: https://www.daltontx.com/
Software Category: AI-Enabled Drug Discovery / Life Sciences Technology
Source: https://www.daltontx.com/blog/daltontx-raises-4-million-seed-financing-to-build-the-intelligence-backbone-of-drug-discovery